The Food and Drug Administration announced on Friday that it rejected Capricor Therapeutics' deramiocel for patients with Duchenne muscular dystrophy. Designed for patients who have already lost the ability to walk, the cell therapy aimed to address a critical therapeutic void. However, the candidate failed in two randomized clinical trials to preserve arm muscle function or stave off heart failure. Consequently, the agency declined to allow the therapy onto the market despite the pressing need for effective interventions.
Key points
Regulating interventions for progressive muscle-wasting conditions remains a persistent c…: Regulating interventions for progressive muscle-wasting conditions remains a persistent challenge for the Food and Drug Administration.
The regulatory decision halts the commercial path for a treatment targeting patients with…: The regulatory decision halts the commercial path for a treatment targeting patients with highly limited therapeutic options.
Clinical failure across two randomized studies directly led to the agency's decision to d…: Clinical failure across two randomized studies directly led to the agency's decision to deny commercial market entry.
Sources checked by our analysis pipeline: 1
The Food and Drug Administration said Friday that it had rejected a cell therapy intended for patients with Duchenne muscular dystrophy developed by Capricor Therapeutics.
The decision to block the treatment, called deramiocel, from reaching the market should have been an easy one for regulators to make. The targeted patient population — teenagers and young men with Duchenne who had already lost the ability to walk — have few treatment options today. Deramiocel didn’t help them either. Capricor conducted two randomized clinical trials. Both failed to show deramiocel could stave off heart failure or preserve muscle function in their arms.
But nothing is straightforward when it comes to regulating drugs for Duchenne, a progressive, muscle-wasting disease.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Surging interest across social media has fueled debate over whether the popular muscle-building compound can enhance mental performance. Scientists emphasize that the brain naturally produces its own supply and restricts entry through the blood-brain barrier, making cognitive improvements unlikely for healthy individuals. Real benefits may ultimately be confined to instances of extreme metabolic fatigue or specific neurological conditions.
Healthcare disruptions in the region are set to escalate as medical professionals push for long-term pay restoration back to 2008 levels. The British Medical Association contends that uncompetitive wages are accelerating staff departures to the Republic of Ireland and mainland Britain. This prolonged dispute threatens wider public service stability, especially with other public sector unions overwhelmingly voting to join future industrial actions.
The disaster in Bayelsa State underscores persistent maritime safety hazards on Nigerian waterways, where mechanical failure and severe overcrowding frequently lead to mass casualties. Search operations remain active as divers seek further victims from a vessel that local residents claim carried roughly 300 passengers. Authorities have launched an investigation into the operators after the pilot abandoned the scene.